Pharmaceutical composition containing caffeoyl quinic acid compound and application of pharmaceutical composition in treatment of rheumatoid arthritis

A caffeoylquinic acid, rheumatoid technology, applied in the direction of drug combination, medical preparations containing active ingredients, organic active ingredients, etc., can solve the problems of inflammation and sequelae treatment stage, and achieve the effect of improving the treatment effect

Pending Publication Date: 2022-08-05
HEILONGJIANG UNIV OF CHINESE MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no specific therapy for rheumatoid arthritis so far, and it is still in the treatment stage of inflammation and sequelae.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing caffeoyl quinic acid compound and application of pharmaceutical composition in treatment of rheumatoid arthritis
  • Pharmaceutical composition containing caffeoyl quinic acid compound and application of pharmaceutical composition in treatment of rheumatoid arthritis
  • Pharmaceutical composition containing caffeoyl quinic acid compound and application of pharmaceutical composition in treatment of rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] 1.1 Test drugs

[0023] Positive control group 1: 3-O-caffeoylquinic acid (3-CQA);

[0024] Positive control group 2: 1,5-O-dicaffeoylquinic acid (1,5-DCQA);

[0025] The test drug group was mixed with 1:3-CQA and 1,5-DCQA in a weight ratio of 1:0.8;

[0026] The test drug group 2:3-CQA and 1,5-DCQA were mixed in a weight ratio of 1:0.6;

[0027] The test drug group 3:3-CQA and 1,5-DCQA were mixed in a weight ratio of 1:0.5;

[0028] The test drug group 4:3-CQA and 1,5-DCQA were mixed in a weight ratio of 1:0.4;

[0029] The test drug group 5:3-CQA and 1,5-DCQA were mixed in a weight ratio of 1:0.3;

[0030] 1.2 Reagents

[0031] Immune grade bovine type II collagen is a product of American Chondrex Company (Catalog No. 20022), 2 mg·ml-1, dissolved in 0.05M acetic acid solution. Freund's incomplete adjuvant (Freund's incomplete adjuvant) is a product of Sigma Company in the United States (10 mL / piece). Rat IgG, IL1-β, TNF-α enzyme chain immunoassay kit, product o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing caffeoyl quinic acid compounds and application of the pharmaceutical composition in treatment of rheumatoid arthritis, and the pharmaceutical composition contains active ingredients: 3-O-caffeoyl quinic acid (3-CQA) and 1, 5-O-dicaffeoyl quinic acid (1, 5-DCQA). The caffeoyl quinic acid compound is further researched, and it is surprisingly found that 3-CQA and 1, 5-DCQA are combined according to a specific proportion range, so that the treatment effect of the caffeoyl quinic acid compound on rheumatoid arthritis is further improved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition containing a caffeoylquinic acid compound and its application in the treatment of rheumatoid arthritis. Background technique [0002] Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease with unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations. disease. The disease occurs in small joints such as hands, wrists, and feet, and is prone to repeated attacks and is distributed symmetrically. In the early stage of the disease, the joints are red, swollen, hot, sore, and dysfunctional. In the late stage, the joints may have varying degrees of stiffness and deformity, accompanied by atrophy of the bones and skeletal muscles, which can easily lead to disability. From the point of view of pathological changes, rheumatoid arthritis is a disease that main...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5377A61P19/02A61P29/00
CPCA61K31/5377A61P19/02A61P29/00A61K2300/00
Inventor姜海
OwnerHEILONGJIANG UNIV OF CHINESE MEDICINE